Kamikihi-to (kkt) rescues axonal and synaptic degeneration associated with memory impairment in a mouse model of alzheimer's disease, 5xfad

International Journal of Neuroscience

Volumn 121, Issue 12, 2011, Pages 641-648

  Tohda, Chihiro ^a   Nakada, Rie ^a   Urano, Takuya ^a   Okonogi, Akira ^b   Kuboyama, Tomoharu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b KANEBO LTD   (Japan)

Author keywords

Alzheimer's disease; Axon; Object recognition; Synapses

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; HERBACEOUS AGENT; KAMIKIHI TO; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; MALE; MEMORY DISORDER; MOUSE; NERVE CELL DEGENERATION; NERVE FIBER DEGENERATION; NONHUMAN; RAT; RECOGNITION;

ALZHEIMER DISEASE; ANIMALS; AXONS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; HUMANS; MALE; MEDICINE, KAMPO; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; SYNAPSES;

EID: 82355160628     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2011.602809     Document Type: Article

References (35)

1. Abdul, H. M., Sama, M. A., Furman, J. L., Mathis, D. M., Beckett, T. L., Weidner, A. M., et al. (2009). Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. Journal of Neuroscience, 29, 12957-12969.
2. Barker, G. R., Bird, F., Alexander, V., & Warburton, E. C. (2007). Recognition memory for objects, place, and temporal order: a disconnection analysis of the role of the medial prefrontal cortex and perirhinal cortex. Journal Neuroscience, 27, 2948-2957. (Pubitemid 46438982)
3. Brendza, R. P., Bacskai, B. J., Cirrito, J. R., Simmons, K. A., Skoch, J. M., Klunk, W. E., et al. (2005). Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. Journal of Clinical Investigation, 115, 428-433. (Pubitemid 40385484)
4. Cai, Y., Xiong, K., Zhang, X. M., Cai, H., Luo, X. G., Feng, J. C., et al. (2010). β-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation. European Journal of Neuroscience, 32, 1223-238.
5. DeCoteau, W. E., & Kesner, R. P. (1998). Effects of hippocampal and parietal cortex lesions on the processing of multiple-object scenes. Behavioral Neuroscience, 112, 68-82. (Pubitemid 28106755)
6. Dickson, T. C., King, C. E., McCormack, G. H., & Vickers, J. C. (1999). Neurochemical diversity of dystrophic neurites in the early and late stages of Alzheimer's disease. Experimental Neurology, 156, 100-110. (Pubitemid 29152987)
7. Dickson, T. C., & Vickers, J. C. (2001). The morphological phenotype of β-amyloid plaques and associated neuritic changes in Alzheimer's disease. Neuroscience, 105, 99-107. (Pubitemid 32722097)
8. Eriksen, J. L., & Janus, C. G. (2007). Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behavior Genetics, 37, 79-100. (Pubitemid 46150856)
9. Ghosh, A. K., Gemma, S., & Tang, J. (2005). β-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics, 5, 399-408.
10. Grace, E. A., & Busciglio, J. (2003). Aberrant activation of focal adhesion proteins mediates fibrillar amyloid β-induced neuronal dystrophy. Journal of Neuroscience, 23, 493-502. (Pubitemid 36139548)
11. Henley, D. B., May, P. C., Dean, R. A., & Siemers, E. R. (2009). Development of semagacestat (LY450139), a functional gammasecretase inhibitor, for the treatment of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 10, 1657-1664.
12. Imbimbo, B. P. (2008). Therapeutic potential of gamma-secretase inhibitors and modulators. Current Topics in Medicinal Chemistry, 8, 54-61. (Pubitemid 351791047)
13. Jacobsen, J. S., Reinhart, P., & Pangalos, M. N. (2005). Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx, 2, 612-626. (Pubitemid 41393269)
14. Joyashiki, E., Matsuya, Y., & Tohda, C. (2011). Sominone improves memory impairments and increases axonal density in Alzheimer's disease model mice, 5XFAD. International Journal of Neuroscience, 121, 181-190.
15. Kuboyama, T., Tohda, C., & Komatsu, K. (2005). Neuritic regeneration and synaptic reconstruction induced by withanolide A. British Journal of Pharmacology, 144, 961-971. (Pubitemid 40593022)
16. Mucke, L. (2009). Neuroscience: Alzheimer's disease. Nature, 461, 895-897.
17. Naito, R., & Tohda, C. (2006). Characterization of antineurodegenerative effects of Polygala tenuifolia in Aβ(25-35)-treated cortical neurons. Biological & Pharmaceutical Bulletin, 29, 1892-1896. (Pubitemid 44338413)
18. Oakley, H.,Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., et al. (2006). Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's diseasemutations: Potential factors in amyloid plaque formation. Journal of Neuroscience, 26, 10129-10140. (Pubitemid 44527407)
19. Ohno,M. (2009). Failures to reconsolidatememory in a mousemodel of Alzheimer's disease. Neurobiology of Learning and Memory, 92, 455-459.
20. Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W. L., et al. (2006).Temporalmemory deficits in Alzheimer'smouse models: Rescue by genetic deletion of BACE1. European Journal of Neuroscience, 23, 251-260.
21. Ohno, M., Cole, S. L., Yasvoina, M., Zhao, J., Citron, M., Berry, R., et al. (2007). BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiology of Disease, 26, 134-145. (Pubitemid 46436493)
22. Pike, C. J., Walencewicz-Wasserman, A. J., Kosmoski, J., Cribbs, D. H., Glabe, C. G., & Cotman, C. W. (1995). Structure-activity analyses of β-amyloid peptides: Contribution of the β25-35 region to aggregation and neurotoxicity. Journal of Neurochemistry, 64, 253-265.
23. Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., et al. (2009). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology, 73, 2061-2070.
24. Soto, P., Griffin, M. A., & Shea, J. E. (2007). New insights into the mechanism of Alzheimer amyloid-beta fibrillogenesis inhibition by N-methylated peptides. Biophysical Journal, 93, 3015-3025. (Pubitemid 350097094)
25. Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S., Iwatsubo, T., Goedert, M., et al. (2005). Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. Journal of Biological Chemistry, 280, 7614-7623. (Pubitemid 40349654)
26. Tohda, C., Hashimoto, I., Kuboyama, T., & Komatsu, K. (2006). Metabolite 1 of protopanaxadiol-type saponins, an axonal regenerative factor, stimulates teneurin-2 linked by PI3-kinase cascade. Neuropsychopharmacology, 31, 1158-1164. (Pubitemid 43971833)
27. Tohda, C., Matsumoto, N., Zou, K., Meselhy,M. R., & Komatsu, K. (2002). Axonal and dendritic extension by protopanaxadiol-type saponins from ginseng drugs in SK-N-SH cells. Japanese Journal of Pharmacology, 90, 254-262. (Pubitemid 35422943)
28. Tohda, C., Matsumoto, N., Zou, K., Meselhy, M. R., & Komatsu, K. (2004). Aβ(25-35)-induced memory impairment, axonal atrophy, and synaptic loss are ameliorated by M1, A metabolite of protopanaxadiol-type saponins. Neuropsychopharmacology, 29, 860-868. (Pubitemid 38526786)
29. Tohda, C., Naito, R., & Joyashiki, E. (2008). Kamikihi-to, a herbal traditional medicine, improves Aβ(25-35)-induced memory impairment and losses of neurites and synapses. BMC Complementary and Alternative Medicine, 8, 49.
30. Tohda, C., Tamura, T., & Komatsu, K. (2003). Repair of amyloid β(25-35)-induced memory impairment and synaptic loss by a Kampo formula, Zokumei-to. Brain Research, 990, 141-147. (Pubitemid 37244069)
31. Tohda, C., Tamura, T., Matsuyama, S., & Komatsu, K. (2006). Promotion of axonal maturation and prevention of memory loss in mice by extracts of Astragalus mongholicus. British Journal of Pharmacology, 149, 532-541. (Pubitemid 44658514)
32. Tsai, J., Grutzendler, J., Duff, K., & Gan,W. B. (2004). Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nature Neuroscience, 7, 1181-1183. (Pubitemid 39426234)
33. Urano, T., & Tohda, C. (2010). Icariin improves memory impairment in Alzheimer's disease model mice (5xFAD) and attenuates amyloid β-induced neurite atrophy. Phytotherapy Research, 24, 1658-1663.
34. Wu, H. Y., Hudry, E., Hashimoto, T., Kuchibhotla, K., Rozkalne, A., Fan, Z., et al. (2010). Amyloid β induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. Journal of Neuroscience, 30, 2636-2649.
35. Zhang, X. M., Cai, Y., Xiong, K., Cai, H., Luo, X. G., Feng, J. C., et al. (2009). β-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: Implications for neuritic plaque development. European Journal of Neuroscience, 30, 2271-2283.